Compare Vaxcyte Inc. Common Stock (PCVX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Sana Biotechnology Inc — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.63B), while Sana Biotechnology Inc trades at $2.33 (market cap $697.51M). The key difference: Vaxcyte Inc. Common Stock is far larger — about 15.2× Sana Biotechnology Inc's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Sana Biotechnology Inc for 24 Days on average.
| PCVX | SANA | |
|---|---|---|
Market Cap | $10.63B | $697.51M |
Volume | 1,525,205 | 2,763,583 |
Sector | Health | Health |
52-Week High | $73.82 | $5.92 |
52-Week Low | $40.32 | $2.33 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $9.26B | $610.76M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sana Biotechnology (SANA) trades at $2.41, down 8.02% in the last session, reflecting a bearish technical trend despite bullish oscillators. The company is pre-revenue with significant losses, reporting a net income of -$244.17 million in 2025 and negative cash flow, while maintaining a price-to-book ratio of 4.51. Recent news highlights active participation in investor conferences and a positive analyst consensus.
The outlook is speculative, with high risk due to no current revenue and substantial cash burn, but potential upside exists if clinical developments succeed, supported by an analyst consensus price target of $8.50. Key risks include funding needs, clinical trial outcomes, and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
